boehringer ingelheim glp-1 initiates Phase 2 clinical trial of Gubra-originated triple receptor agonist for people living with overweight and obesity Boehringer moves Wegovy competitor into
Pay in 4 interest-free payments of $7.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5



























